Vitreal penetration of oral moxifloxacin in humans.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 18327141.
- Also identified by DOI 10.1097/IAE.0b013e31814fb0ed.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To investigate the vitreal penetration of moxifloxacin after oral administration. Prospective, nonrandomized clinical series. Twenty-four patients (mean age = 62.8 years) undergoing elective pars plana vitrectomy were assigned to a dosing group: control (n = 3), which received no medication; single-dose (n = 11), which received one 400 mg oral dose of moxifloxacin 3 hours before surgery; and five-dose (n = 10), which received one 400 mg dose on each of the 4 days preceding surgery and a fifth dose 3 hours before surgery. Vitreous samples were obtained and analyzed. Control, below quantifiable levels; single-dose, 0.572 +/- 0.239 microg/mL; and five-dose, 1.200 +/- 0.645 microg/mL. Five doses of oral moxifloxacin lead to higher intravitreal drug concentrations than single-dose administration. Both regimens, however, achieve levels that exceed the MIC90 of many bacteria implicated in postoperative endophthalmitis.
Medical subject headings
- Anti-Infective Agents
- Aza Compounds
- Quinolines
- Vitreous Body